CL2011001490A1 - Sal hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico y sus formas cristalinas; composicion farmaceutica; y su uso en la prevencion o tratamiento de rechazo de trasplantes, enfermedades autoinmunes, enfermedades alergicas, entre otras. - Google Patents

Sal hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico y sus formas cristalinas; composicion farmaceutica; y su uso en la prevencion o tratamiento de rechazo de trasplantes, enfermedades autoinmunes, enfermedades alergicas, entre otras.

Info

Publication number
CL2011001490A1
CL2011001490A1 CL2011001490A CL2011001490A CL2011001490A1 CL 2011001490 A1 CL2011001490 A1 CL 2011001490A1 CL 2011001490 A CL2011001490 A CL 2011001490A CL 2011001490 A CL2011001490 A CL 2011001490A CL 2011001490 A1 CL2011001490 A1 CL 2011001490A1
Authority
CL
Chile
Prior art keywords
ethyl
imino
trifluoro
methyl
azetidine
Prior art date
Application number
CL2011001490A
Other languages
English (en)
Spanish (es)
Inventor
Lech Ciszewski
La Cruz Marilyn De
Piotr H Karpinski
Michael Mutz
Christian Riegert
Caspar Vogel
Ricardo Schneeberger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42236293&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001490(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2011001490A1 publication Critical patent/CL2011001490A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2011001490A 2008-12-18 2011-06-17 Sal hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico y sus formas cristalinas; composicion farmaceutica; y su uso en la prevencion o tratamiento de rechazo de trasplantes, enfermedades autoinmunes, enfermedades alergicas, entre otras. CL2011001490A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20305308P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
CL2011001490A1 true CL2011001490A1 (es) 2012-01-13

Family

ID=42236293

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001490A CL2011001490A1 (es) 2008-12-18 2011-06-17 Sal hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico y sus formas cristalinas; composicion farmaceutica; y su uso en la prevencion o tratamiento de rechazo de trasplantes, enfermedades autoinmunes, enfermedades alergicas, entre otras.

Country Status (36)

Country Link
US (6) US20120115840A1 (fr)
EP (2) EP2379497B1 (fr)
JP (1) JP5627597B2 (fr)
KR (5) KR20110096584A (fr)
CN (2) CN102256943A (fr)
AR (3) AR074694A1 (fr)
AU (1) AU2009335924B2 (fr)
BR (1) BRPI0923176B8 (fr)
CA (2) CA2747437C (fr)
CL (1) CL2011001490A1 (fr)
CO (1) CO6390104A2 (fr)
CY (2) CY1114662T1 (fr)
DK (2) DK2379497T3 (fr)
EC (1) ECSP11011210A (fr)
ES (2) ES2436197T3 (fr)
HK (1) HK1159631A1 (fr)
HR (2) HRP20131106T1 (fr)
HU (1) HUE034819T2 (fr)
IL (3) IL253845B (fr)
JO (1) JO2894B1 (fr)
LT (1) LT2676953T (fr)
MA (1) MA32961B1 (fr)
MX (1) MX2011006609A (fr)
MY (1) MY152669A (fr)
NZ (1) NZ593061A (fr)
PE (2) PE20120336A1 (fr)
PL (2) PL2676953T3 (fr)
PT (2) PT2676953T (fr)
RS (2) RS56110B1 (fr)
RU (1) RU2518114C3 (fr)
SG (1) SG171785A1 (fr)
SI (2) SI2676953T1 (fr)
TW (2) TWI591055B (fr)
UY (1) UY32330A (fr)
WO (1) WO2010080409A1 (fr)
ZA (1) ZA201103709B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093161A1 (fr) 2011-01-07 2012-07-12 Novartis Ag Formulations d'immunosuppresseurs
WO2012095853A1 (fr) 2011-01-10 2012-07-19 Novartis Pharma Ag Formulations à libération modifiée comprenant des modulateurs des récepteurs sip
IL305337A (en) * 2014-04-10 2023-10-01 Novartis Ag A therapeutic regimen containing an immediate release dose of an S1P modulator
PT3129006T (pt) 2014-04-10 2021-04-09 Novartis Ag Formulação imunossupressora
WO2016135644A1 (fr) 2015-02-26 2016-09-01 Novartis Ag Traitement de maladie auto-immune chez un patient recevant en outre un bêtabloquant
WO2017120124A1 (fr) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Modulateurs azétidine du récepteur de la sphingosine 1-phosphate
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
JP7271517B2 (ja) * 2017-09-27 2023-05-11 ノバルティス アーゲー シポニモドを含む非経口製剤
JP2020535175A (ja) * 2017-09-27 2020-12-03 ドクター レディズ ラボラトリーズ リミテッド シポニモド、その塩およびその固体状態フォームの調製のためのプロセス
EP3687531A1 (fr) * 2017-09-29 2020-08-05 Novartis AG Schéma posologique de siponimod
MX2020007268A (es) * 2017-09-29 2020-08-17 Novartis Ag Regimen de dosificacion de siponimod.
WO2019144094A1 (fr) 2018-01-22 2019-07-25 Teva Pharmaceuticals International Gmbh Acide fumarique siponimod cristallin et polymorphes de celui-ci
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020161632A1 (fr) * 2019-02-07 2020-08-13 Dr. Reddy’S Laboratories Limited Formes solides cristallines de siponimod
US20220144768A1 (en) * 2019-02-27 2022-05-12 Dr. Reddy's Laboratories Limited Solid state forms of siponimod
EP3972954A1 (fr) 2019-05-21 2022-03-30 Synthon B.V. Sel d'acide maléique et d'acide fumarique siponimod
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
EP4139282A2 (fr) * 2020-05-29 2023-03-01 Cipla Limited Procédés de préparation de modulateurs du récepteur de la sphingosine 1-phosphate et leurs formes solides
WO2022064007A1 (fr) 2020-09-25 2022-03-31 Synthon B.V. Sels et co-cristaux de siponimod
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
WO2022127863A1 (fr) * 2020-12-16 2022-06-23 苏州晶云药物科技股份有限公司 Formes cristallines de sel hémifumarate d'un composé d'acide carboxylique et procédé de préparation associé
WO2022199865A1 (fr) 2021-03-26 2022-09-29 Olon S.P.A. Nouveau composé cristallin d'hémifumarate de siponimod
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
ES2073868T3 (es) * 1991-06-04 1995-08-16 Fujisawa Pharmaceutical Co Una composicion profilactica/terapeutica para la pleuroneumonia del cerdo.
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
WO1994028967A1 (fr) * 1993-06-08 1994-12-22 Hisamitsu Pharmaceutical Co., Inc. Systeme d'iontophorese
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP1110953B1 (fr) 1995-03-30 2009-10-28 Pfizer Products Inc. Dérivés de quinazolinone
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE69619114T2 (de) 1995-07-06 2002-10-02 Novartis Ag Pyrolopyrimidine und verfahren zu ihrer herstellung
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69725585T2 (de) * 1996-04-04 2004-07-01 Sankyo Co., Ltd. Phenylalkylcarbonsäure-derivate
EP0892789B2 (fr) 1996-04-12 2009-11-18 Warner-Lambert Company LLC Inhibiteurs irreversibles de tyrosine kinases
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0907642B1 (fr) 1996-06-24 2005-11-02 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
WO1998002441A2 (fr) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathogènes
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (fr) 1996-09-13 1998-03-19 Gerald Mcmahon Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
DE69942097D1 (de) 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP4731016B2 (ja) 1998-12-22 2011-07-20 ジェネンテック， インコーポレイテッド 血管内皮細胞増殖因子アンタゴニストとその用途
DE60028740T2 (de) 1999-03-30 2007-05-24 Novartis Ag Phthalazinderivate zur behandlung von entzündlichen erkrankungen
EP1309556B1 (fr) * 2000-12-29 2004-11-24 Pfizer Limited Fumarate d'amlodipine
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2004110330A1 (fr) 2003-06-13 2004-12-23 Stephen Dichiera Support de lit reglable et lit
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
BRPI0518674A2 (pt) * 2004-11-29 2008-12-02 Novartis Ag regime de dosagem de um agonista de receptor s1p
KR20080031936A (ko) * 2005-08-04 2008-04-11 노파르티스 아게 빌다글립틴의 염
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP2010508370A (ja) * 2006-11-07 2010-03-18 ノバルティス アーゲー ヘミフマル酸アリスキレンの結晶形

Also Published As

Publication number Publication date
NZ593061A (en) 2013-08-30
KR20180006492A (ko) 2018-01-17
UY32330A (es) 2010-07-30
EP2676953A1 (fr) 2013-12-25
JP2012512881A (ja) 2012-06-07
US20220402870A1 (en) 2022-12-22
CY1114662T1 (el) 2016-10-05
BRPI0923176A2 (pt) 2016-02-16
SI2379497T1 (sl) 2013-12-31
PL2676953T3 (pl) 2017-09-29
TWI500603B (zh) 2015-09-21
HUE034819T2 (en) 2018-02-28
BRPI0923176A8 (pt) 2017-09-12
CO6390104A2 (es) 2012-02-29
KR20160129915A (ko) 2016-11-09
HK1159631A1 (fr) 2012-08-03
DK2676953T3 (en) 2017-07-03
IL213071A0 (en) 2011-07-31
PL2379497T3 (pl) 2014-01-31
BRPI0923176B8 (pt) 2021-05-25
TW201509909A (zh) 2015-03-16
US20180118678A1 (en) 2018-05-03
HRP20170916T1 (hr) 2017-09-22
PT2379497E (pt) 2013-11-29
TWI591055B (zh) 2017-07-11
EP2379497B1 (fr) 2013-08-21
EP2676953B1 (fr) 2017-03-22
ECSP11011210A (es) 2011-08-31
KR101885052B1 (ko) 2018-08-02
KR20160064245A (ko) 2016-06-07
US20140005162A1 (en) 2014-01-02
BRPI0923176B1 (pt) 2020-12-01
AU2009335924B2 (en) 2012-11-08
AU2009335924A1 (en) 2011-06-30
LT2676953T (lt) 2017-06-26
AR074694A1 (es) 2011-02-02
SG171785A1 (en) 2011-07-28
US20120115840A1 (en) 2012-05-10
JP5627597B2 (ja) 2014-11-19
DK2379497T3 (da) 2013-11-25
US20210323915A1 (en) 2021-10-21
MX2011006609A (es) 2011-06-30
AR121635A2 (es) 2022-06-22
HRP20131106T1 (hr) 2013-12-20
AR112227A2 (es) 2019-10-02
CA2747437A1 (fr) 2010-07-15
RS53041B (en) 2014-04-30
MY152669A (en) 2014-10-31
JO2894B1 (en) 2015-09-15
IL253845B (en) 2022-08-01
RU2518114C3 (ru) 2021-11-24
EP2379497A1 (fr) 2011-10-26
ES2631203T3 (es) 2017-08-29
WO2010080409A1 (fr) 2010-07-15
ES2436197T3 (es) 2013-12-27
MA32961B1 (fr) 2012-01-02
IL253845A0 (en) 2017-09-28
TW201035048A (en) 2010-10-01
IL294514A (en) 2022-09-01
RU2518114C2 (ru) 2014-06-10
US20230357142A9 (en) 2023-11-09
CY1119037T1 (el) 2018-01-10
US20150175536A1 (en) 2015-06-25
CN104803902A (zh) 2015-07-29
PE20142374A1 (es) 2015-01-30
PE20120336A1 (es) 2012-04-30
PT2676953T (pt) 2017-06-29
CA2951479A1 (fr) 2010-07-15
CA2747437C (fr) 2018-08-21
RS56110B1 (sr) 2017-10-31
SI2676953T1 (sl) 2017-07-31
KR20170062554A (ko) 2017-06-07
RU2011129222A (ru) 2013-01-27
ZA201103709B (en) 2012-01-25
CN102256943A (zh) 2011-11-23
KR20110096584A (ko) 2011-08-30

Similar Documents

Publication Publication Date Title
CL2011001490A1 (es) Sal hemifumarato del acido 1-(4-{1-[(e)-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxilico y sus formas cristalinas; composicion farmaceutica; y su uso en la prevencion o tratamiento de rechazo de trasplantes, enfermedades autoinmunes, enfermedades alergicas, entre otras.
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
CL2017003445A1 (es) Formas solidas y formulaciones de compuestos de imidazopirazina.
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CR20180185A (es) Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales
DOP2012000067A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de enzima de disociacion de app de sitio beta ( bace), composiciones, y su uso
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
CU23614B7 (es) Forma cristalina beta del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
DOP2007000051A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
HN2012001162A (es) Triazolopiridinas
UY31072A1 (es) Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
MX2011009847A (es) Agentes antihelminticos y su uso.
UY32494A (es) Nuevas 2,4-diaminopirimidinas, sales farmacéuticas de las mismas, composiciones conteniéndolas y aplicaciones
ECSP10010690A (es) Composiciones líquidas de limpieza de faena liviana y métodos de manufactura y uso de los mismos.
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
BR112014013138A2 (pt) anilinas substituídas como antagonistas de ccr(4)